Market Highlights:
Artificial tears is refer as the lubricant eye drops which is used for treatment of the dryness and irritation associated with the deficient tear production in keratoconjunctivitis sicca which is commonly called as dry eyes. They are also popularly used for moisten the contact lenses and also in testing the eye. Artificial tears also help in maintaining the moisture on the outer surface of the eye. This kind of eye drop is also used to treat eyes that results from ageing, a medical condition, certain medications, eye surgery or environmental factors, like smoky or windy conditions. Artificial tears can be available in the market without any prescription. some of the artificial tears contain electrolytes. These kind of additives may promote healing of the eye surface. Artificial tears may also contain thickening agents, which keeps the solution on the eye surface for longer period The market study is being classified by Type (Artificial Tear Liquid and Artificial Tear Ointment), by Application (Dry Eyes Treatment, Contact Lenses Moisten and Others) and major geographies with country level break-up that includes South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

Key Players:
The prominent players in the Artificial Tears are Allergan (Republic of Ireland), Alcon (Novartis) (United States), Bausch & Lomb (United States), Abbott (United States), Santen Pharmaceutical (Japan), Ursapharm (Germany), Rohto (Japan), Similasan Corporation (United States), Johnson & Johnson (United States) and Ocusoft (United States).

The End User, such as Hospital, is boosting the Artificial Tears market. Additionally, the rising demand from SMEs and various industry verticals, macro-economic growth are the prime factors driving the growth of the market.

Major Market Development Highlights
Alcon, the global leader in eye care and a division of Novartis, announced that it has acquired Tear Film Innovations, Inc. (“Tear Film”), a privately-held company and manufacturer of the iLux Device, an innovative therapeutic device used to treat Meibomian Gland Dysfunction, a leading cause of dry eye
Alcon, the global leader in eye care and a division of Novartis, recently launched a new website, AlconScience.com, for US- and Canada-based Eye Care Professionals (ECPs) and academic institutions. The new Medical Affairs website consolidates information about Alcon’s scientific, academic, and related activities into one portal

Key Questions Answered in the Report
What will the Artificial Tears Market size and the growth rate be in Future?
What are the key factors driving the Artificial Tears Market?
What are the key market trends and macro-economic impacting the growth of the Artificial Tears Market?
What are the challenges to market growth?
Who are the key vendors in the Artificial Tears Market?
What are the market opportunities and threats faced by the vendors in the Artificial Tears Market?
Trending factors influencing the market shares of the Players.
What are the key outcomes of the five forces analysis of the Artificial Tears Market?

Refer complete Table of Content of Artificial Tears Market Study

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Artificial Tears market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Artificial Tears market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Artificial tears producers, Artificial tears suppliers, Artificial tears retailers and wholesalers, Pharmaceuticals, Research firms and Healthcare industry.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.